Decitabine for injection 50mg Taj Pharma

  1. Name of the medicinal product

Deitabine for Injection 50mg/Vial Taj Pharma

  1. Qualitative and quantitative composition

Each Lyophilized vial contains:
Decitabine 50mg
Excipients: Q.S.

Excipients with known effect

For the full list of excipients, see section 6.1.

  1. Pharmaceutical form

Lyophilized powder for injection

  1. Clinical particulars
  • Therapeutic indications

Deitabine injection is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

  • Posology and method of administration

Deitabine injection administration must be initiated under the supervision of physicians experienced in the use of chemotherapeutic medicinal products.

Posology

In a treatment cycle, Deitabine injection is administered at a dose of 20mg/mbody surface area by intravenous infusion over 1 hour repeated daily for 5 consecutive days (i.e., a total of 5 doses per treatment cycle). The total daily dose must not exceed 20mg/m2 and the total dose per treatment cycle must not exceed 100mg/m2. If a dose is missed, treatment should be resumed as soon as possible. The cycle should be repeated every 4 weeks depending on the patient’s clinical response and observed toxicity. It is recommended that patients be treated for a minimum of 4 cycles; however, a complete or partial remission may take longer than 4 cycles to be obtained. Treatment may be continued as long as the patient shows response, continues to benefit or exhibits stable disease, i.e., in the absence of overt progression.

If after 4 cycles, the patient’s haematological values (e.g., platelet counts or absolute neutrophil count), have not returned to pre-treatment levels or if disease progression occurs (peripheral blast counts are increasing or bone marrow blast counts are worsening), the patient may be considered to be a non-responder and alternative therapeutic options to Deitabine injection should be considered.

Pre-medication for the prevention of nausea and vomiting is not routinely recommended but may be administered if required.

Management of myelosuppression and associated complications

Myelosuppression and adverse events related to myelosuppression (thrombocytopaenia, anaemia, neutropaenia, and febrile neutropaenia) are common in both treated and untreated patients with AML. Complications of myelosuppression include infections and bleeding. Treatment may be delayed at the discretion of the treating physician, if the patient experiences myelosuppression-associated complications, such as those described below:

  • Febrile neutropaenia (temperature ≥ 38.5°C and absolute neutrophil count < 1,000/µL) Active viral, bacterial or fungal infection (i.e., requiring intravenous anti-infectives or extensive supportive care)
  • Haemorrhage (gastrointestinal, genito-urinary, pulmonary with platelets < 25,000/µL or any central nervous system haemorrhage)

Treatment with Deitabine injection may be resumed once these conditions have improved or have been stabilised with adequate treatment (anti-infective therapy, transfusions, or growth factors).

In clinical studies, approximately one-third of patients receiving Deitabine injection required a dose-delay. Dose reduction is not recommended.

Paediatric population

Deitabine injection should not be used in children with AML aged < 18 years, because efficacy was not established. Currently available data are described in sections 4.8, 5.1, and 5.2.

Hepatic impairment

Studies in patients with hepatic impairment have not been conducted. The need for dose adjustment in patients with hepatic impairment has not been evaluated. If worsening hepatic function occurs, patients should be carefully monitored (see sections 4.4 and 5.2).

Renal impairment

Studies in patients with renal impairment have not been conducted. The need for dose adjustment in patients with renal impairment has not been evaluated (see section 4.4 and 5.2).

Method of administration

Deitabine injection is administered by intravenous infusion. A central venous catheter is not required.

For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.

  • Contraindications

Hypersensitivity to decitabine or to any of the excipients, listed in section 6.1.

Breast-feeding (see section 4.6)

  • Special warnings and precautions for use

Myelosuppression

Myelosuppression and complications of myelosuppression, including infections and bleeding that occur in patients with AML may be exacerbated with Deitabine injection treatment. Therefore, patients are at increased risk for severe infections (due to any pathogen such as bacterial, fungal and viral), with potentially fatal outcome (see section 4.8). Patients should be monitored for signs and symptoms of infection and treated promptly.

In clinical studies, the majority of patients had baseline Grade 3/4 myelosuppression. In patients with baseline Grade 2 abnormalities, worsening of myelosuppression was seen in most patients and more frequently than in patients with baseline Grade 1 or 0 abnormalities. Myelosuppression caused by Deitabine injection is reversible. Complete blood and platelet counts should be performed regularly, as clinically indicated and prior to each treatment cycle. In the presence of myelosuppression or its complications, treatment with Deitabine injection may be interrupted and/or supportive measures instituted (see sections 4.2 and 4.8).

Respiratory, thoracic and mediastinal disorders

Cases of interstitial lung disease (ILD) (including pulmonary infiltrates, organising pneumonia and pulmonary fibrosis) without signs of infectious aetiology have been reported in patients receiving decitabine. Careful assessment of patients with an acute onset or unexplained worsening of pulmonary symptoms should be performed to exclude ILD. If ILD is confirmed, appropriate treatment should be initiated (see section 4.8).

Hepatic impairment

Use in patients with hepatic impairment has not been established. Caution should be exercised in the administration of Deitabine injection to patients with hepatic impairment and in patients who develop signs or symptoms of hepatic impairment. Liver function tests should be performed prior to initiation of therapy and prior to each treatment cycle, and as clinically indicated (see sections 4.2 and 5.2).

Renal impairment

Use in patients with severe renal impairment has not been studied. Caution should be exercised in the administration of Deitabine injection to patients with severe renal impairment (Creatinine Clearance [CrCl] < 30ml/min). Renal function tests should be performed prior to initiation of therapy and prior to each treatment cycle, and as clinically indicated (see section 4.2).

Cardiac disease

Patients with a history of severe congestive heart failure or clinically unstable cardiac disease were excluded from clinical studies and therefore, the safety and efficacy of Deitabine injection in these patients has not been established. Cases of cardiomyopathy with cardiac decompensation, in some cases reversible after treatment discontinuation, dose reduction or corrective treatment, have been reported in the postmarketing setting. Patients, especially those with cardiac disease history, should be monitored for signs and symptoms of heart failure.

Excipients

This medicine contains 0.5 mmol potassium per vial. After reconstitution and dilution of the solution for intravenous infusion, this medicine contains less than 1 mmol (39mg) of potassium per dose, i.e. essentially ‘potassium- free’.

This medicine contains 0.29 mmol (6.67mg) sodium per vial. After reconstitution and dilution of the solution for intravenous infusion, this medicine contains between 13.8mg-138mg (0.6-6 mmol) sodium per dose (depending on the infusion fluid for dilution), equivalent to 0.7-7% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

  • Interaction with other medicinal products and other forms of interaction

No formal clinical drug interaction studies with decitabine have been conducted.

There is the potential for a drug-drug interaction with other agents which are also activated by sequential phosphorylation (via intracellular phosphokinase activities) and/or metabolised by enzymes implicated in the inactivation of decitabine (e.g., cytidine deaminase). Therefore, caution should be exercised if these active substances are combined with decitabine.

Impact of co-administered medicinal products on decitabine

Cytochrome (CYP) 450-mediated metabolic interactions are not anticipated as decitabine metabolism is not mediated by this system but by oxidative deamination.

Impact of decitabine on co-administered medicinal products

Given its low in vitro plasma protein binding (< 1%), decitabine is unlikely to displace co-administered medicinal products from their plasma protein binding. Decitabine has been shown to be a weak inhibitor of P-gp mediated transport in vitro and is therefore, also not expected to affect P-gp mediated transport of co-administered medicinal products (see section 5.2).

  • Fertility, pregnancy and lactation

Women of childbearing potential/Contraception in males and females

Women of childbearing potential must use effective contraceptive measures and avoid becoming pregnant while being treated with Deitabine injection. The time period following treatment with Deitabine injection where it is safe to become pregnant is unknown. Men should use effective contraceptive measures and be advised to not father a child while receiving Deitabine injection, and for 3 months following completion of treatment (see section 5.3).

The use of decitabine with hormonal contraceptives has not been studied.

Pregnancy

There are no adequate data on the use of Deitabine injection in pregnant women. Studies have shown that decitabine is teratogenic in rats and mice (see section 5.3). The potential risk for humans is unknown. Based on results from animal studies and its mechanism of action, Deitabine injection should not be used during pregnancy and in women of childbearing potential not using effective contraception. If Deitabine injection is used during pregnancy, or if a patient becomes pregnant while receiving this medicinal product, the patient should be apprised of the potential hazard to the foetus.

Breast-feeding

It is not known whether decitabine or its metabolites are excreted in breast milk. Deitabine injection is contraindicated during breast-feeding; therefore, if treatment with this medicine is required, breast-feeding must be discontinued (see section 4.3).

Fertility

No human data on the effect of decitabine on fertility are available. In non-clinical animal studies, decitabine alters male fertility and is mutagenic. Because of the possibility of infertility as a consequence of Deitabine injection therapy, men should seek advice on conservation of sperm and female patients of childbearing potential should seek consultation regarding oocyte cryopreservation prior to initiation of treatment.

  • Effects on ability to drive and use machines

Deitabine injection has moderate influence on the ability to drive and use machines. Patients should be advised that they may experience undesirable effects such as anaemia during treatment. Therefore, caution should be recommended when driving a car or operating machines.

  • Undesirable effects

Summary of the safety profile

The most common adverse drug reactions (≥ 35%) reported are pyrexia, anaemia and thrombocytopaenia.

The most common Grade 3/4 adverse drug reactions (≥ 20%) included pneumonia, thrombocytopaenia, neutropaenia, febrile neutropaenia and anaemia.

In clinical studies, 30% of patients treated with Deitabine injection and 25% of patients treated in the comparator arm had adverse events with an outcome of death during treatment or within 30 days after the last dose of study drug.

In the Deitabine injection treatment group, there was a higher incidence of treatment discontinuation due to adverse events in women compared to men (43% versus 32%).

Tabulated list of adverse drug reactions

Adverse drug reactions reported in 293 AML patients treated with Deitabine injection are summarised in Table 1. The following table reflects data from AML clinical studies and from post-marketing experience. The adverse drug reactions are listed by frequency category. Frequency categories are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (frequency cannot be estimated from the available data).

Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness.

Table 1: Adverse drug reactions identified with Deitabine injection
System Organ Class Frequency (all Grades) Adverse Drug Reaction Frequency
All Gradesa

(%)

Grades 3-4a

(%)

Infections and infestations Very common pneumonia* 24 20
urinary tract infection* 15 7
All other infections (viral, bacterial, fungal)*, b, c, d 63 39
Common septic shock* 6 4
sepsis* 9 8
sinusitis 3 1
Blood and lymphatic disorders Very common febrile neutropaenia* 34 32
neutropaenia* 32 30
thrombocytopaenia*, e 41 38
anaemia 38 31
leukopaenia 20 18
Uncommon pancytopaenia* < 1 < 1
Immune system disorders Common hypersensitivity including anaphylactic reactionf 1 < 1
Metabolism and nutrition disorders Very common hyperglycaemia 13 3
Nervous system disorders Very common headache 16 1
Cardiac disorders Uncommon Cardiomyopathy < 1 < 1
Respiratory, thoracic and mediastinal disorders Very common epistaxis 14 2
Not known interstitial lung disease Not known Not known
Gastrointestinal disorders Very common diarrhoea 31 2
vomiting 18 1
nausea 33 < 1
Common stomatitis 7 1
Not known enterocolitis, including neutropaenic colitis, caecitis* Not known Not known
Hepatobiliary disorders Very common hepatic function abnormal 11 3
Common hyperbilirubinaemiag 5 <1
Skin and subcutaneous tissue disorders Uncommon acute febrile neutrophilic dermatosis (Sweet’s syndrome) < 1 NA
General disorders and administration site conditions Very common pyrexia 48 9
a Worst National Cancer Institute Common Terminology Criteria for Adverse Events Grade.

b Excluding pneumonia, urinary tract infection, sepsis, septic shock and sinusitis.

c The most frequently reported “other infections” in study DACO-016 were: oral herpes, oral candidiasis, pharyngitis, upper respiratory tract infection, cellulitis, bronchitis, nasopharyngitis.

d Including enterocolitis infectious.

e Including haemorrhage associated with thrombocytopaenia, including fatal cases.

f Including preferred terms hypersensitivity, drug hypersensitivity, anaphylactic reaction, anaphylactic shock, anaphylactoid reaction, anaphylactoid shock.

g In clinical studies in AML and myelodysplastic syndrome (MDS), the reporting frequency for hyperbilirubinaemia was 11% for All Grades and 2% for Grade 3-4.

* Includes events with a fatal outcome.

NA = Not applicable

Description of selected adverse drug reactions

Haematologic adverse drug reactions

The most commonly reported haematologic adverse drug reactions associated with Deitabine injection treatment included febrile neutropaenia, thrombocytopaenia, neutropaenia, anaemia and leukopaenia.

Serious bleeding-related adverse drug reactions, some of which lead to a fatal outcome, such as central nervous system (CNS) haemorrhage (2%) and gastrointestinal (GI) haemorrhage (2%), in the context of severe thrombocytopaenia, were reported in patients receiving decitabine.

Haematological adverse drug reactions should be managed by routine monitoring of complete blood counts and early administration of supportive treatments as required. Supportive treatments include, administration of prophylactic antibiotics and/or growth factor support (e.g., G-CSF) for neutropaenia and transfusions for anaemia or thrombocytopaenia according to institutional guidelines. For situations where decitabine administration should be delayed, see section 4.2.

Infections and infestations adverse drug reactions

Serious infection-related adverse drug reactions, with potentially fatal outcome, such as septic shock, sepsis, pneumonia, and other infections (viral, bacterial and fungal) were reported in patients receiving decitabine.

Gastrointestinal disorders

Occurrences of enterocolitis, including neutropaenic colitis, caecitis have been reported during treatment with decitabine. Enterocolitis may lead to septic complications and may be associated with fatal outcome.

Respiratory, thoracic and mediastinal disorders

Cases of interstitial lung disease (including pulmonary infiltrates, organising pneumonia and pulmonary fibrosis) without signs of infectious aetiology have been reported in patients receiving decitabine.

Paediatric population

The safety assessment in paediatric patients is based on the limited safety data from a Phase I/II study to evaluate pharmacokinetics, safety and efficacy of Deitabine injection in paediatric patients (aged 1 to 14 years) with relapsed or refractory AML (n = 17) (see section 5.1). No new safety signal was observed in this paediatric study.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

  • Overdose

There is no direct experience of human overdose and no specific antidote. However, early clinical study data in published literature at doses greater than 20 times higher than the current therapeutic dose, reported increased myelosuppression including prolonged neutropaenia and thrombocytopaenia. Toxicity is likely to manifest as exacerbations of adverse drug reactions, primarily myelosuppression. Treatment for overdose should be supportive.

  1. Pharmacological properties
    • Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, antimetabolites, pyrimidine analogues; Mechanism of action

Decitabine (5-aza-2′-deoxycytidine) is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumour suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.

Clinical experience

The use of Deitabine injection was studied in an open-label, randomised, multicentre Phase III study (DACO-016) in subjects with newly diagnosed de novo or secondary AML according to the WHO classification. Deitabine injection (n = 242) was compared to treatment choice (TC, n = 243) which consisted of patient’s choice with physician’s advice of either supportive care alone (n = 28, 11.5%) or 20mg/m2 cytarabine subcutaneously once daily for 10 consecutive days repeated every 4 weeks (n = 215, 88.5%). Deitabine injection was administered as a 1-hour intravenous infusion of 20mg/m2 once daily for 5 consecutive days repeated every 4 weeks.

Subjects who were considered candidates for standard induction chemotherapy were not included in the study as shown by the following baseline characteristics. The median age for the intent-to-treat (ITT) population was 73 years (range 64 to 91 years). Thirty-six percent of subjects had poor-risk cytogenetics at baseline. The remainder of the subjects had intermediate-risk cytogenetics. Patients with favourable cytogenetics were not included in the study. Twenty-five percent of subjects had an ECOG performance status ≥ 2. Eighty-one percent of subjects had significant comorbidities (e.g., infection, cardiac impairment, pulmonary impairment). The number of patients treated with Deitabine injection by racial group was White 209 (86.4%) and Asian 33 (13.6%).

The primary endpoint of the study was overall survival. The secondary endpoint was complete remission rate that was assessed by independent expert review. Progression-free survival and Event-free survival were tertiary endpoints.

The median overall survival in the –ITT population was 7.7 months in subjects treated with Deitabine injection compared to 5.0 months for subjects in the TC arm (hazard ratio 0.85; 95% CI: 0.69, 1.04, p = 0.1079). The difference did not reach statistical significance, however, there was a trend for improvement in survival with a 15% reduction in the risk of death for subjects in the Deitabine injection arm (Figure 1). When censored for potentially disease modifying subsequent therapy (i.e., induction chemotherapy or hypomethylating agent) the analysis for overall survival showed a 20% reduction in the risk of death for subjects in the Deitabine injection arm [HR = 0.80, (95% CI: 0.64, 0.99), p-value = 0.0437)].

Figure 1. Overall survival (ITT population).

In an analysis with an additional 1 year of mature survival data, the effect of Deitabine injection on overall survival demonstrated a clinical improvement compared to the TC arm (7.7 months vs. 5.0 months, respectively, hazard ratio = 0.82, 95% CI: 0.68, 0.99, nominal p-value = 0.0373, Figure 2).

Figure 2. Analysis of mature overall survival data (ITT population).

Based on the initial analysis in the ITT population, a statistically significant difference in complete remission rate (CR + CRp) was achieved in favour of subjects in the Deitabine injection arm, 17.8% (43/242) compared to the TC arm, 7.8% (19/243); treatment difference 9.9% (95% CI: 4.07; 15.83), p = 0.0011. The median time to best response and median duration of best response in patients who achieved a CR or CRp were 4.3 months and 8.3 months, respectively. Progression-free survival was significantly longer for subjects in the Deitabine injection arm, 3.7 months (95% CI: 2.7, 4.6) compared with subjects in the TC arm, 2.1 months (95% CI: 1.9, 3.1); hazard ratio 0.75 (95% CI: 0.62, 0.91), p = 0.0031. These results as well as other endpoints are shown in Table 2.

Table 2: Other efficacy endpoints for Study DACO-016 (ITT population)
Outcomes Deitabine injection

n = 242

TC (combined group)

n = 243

p-value
CR + CRp 43 (17.8%) 19 (7.8%) 0.0011
OR = 2.5

(1.40, 4.78)b

CR 38 (15.7%) 18 (7.4%)
EFSa 3.5

(2.5, 4.1)b

2.1

(1.9, 2.8)b

0.0025
HR = 0.75

(0.62, 0.90)b

PFSa 3.7

(2.7, 4.6)b

2.1

(1.9, 3.1)b

0.0031
HR = 0.75

(0.62, 0.91)b

CR = complete remission; CRp = complete remission with incomplete platelet recovery, EFS = event-free survival, PFS = progression-free survival, OR = odds ratio, HR = hazard ratio

– = Not evaluable

a Reported as median months

b 95% confidence intervals

Overall survival and complete remission rates in pre-specified disease-related sub-groups (i.e., cytogenetic risk, Eastern Cooperative Oncology Group [ECOG] score, age, type of AML, and baseline bone marrow blast count) were consistent with results for the overall study population.

The use of Deitabine injection as initial therapy was also evaluated in an open-label, single-arm, Phase II study (DACO-017) in 55 subjects > 60 years with AML according to the WHO classification. The primary endpoint was complete remission (CR) rate that was assessed by independent expert review. The secondary endpoint of the study was overall survival. Deitabine injection was administered as a 1-hour intravenous infusion of 20mg/m2 once daily for 5 consecutive days repeated every 4 weeks. In the ITT analysis, a CR rate of 23.6% (95% CI: 13.2, 37) was observed in 13/55 subjects treated with Deitabine injection. The median time to CR was 4.1 months, and the median duration of CR was 18.2 months. The median overall survival in the ITT population was 7.6 months (95% CI: 5.7, 11.5).

The efficacy and safety of Deitabine injection has not been evaluated in patients with acute promyelocytic leukaemia or CNS leukaemia.

Paediatric population

A Phase I/II open-label, multicentre study evaluated the safety and efficacy of Deitabine injection in sequential administration with cytarabine in children aged 1 month to < 18 years with relapsed or refractory AML. A total of 17 subjects were enrolled and received Deitabine injection 20mg/m2 in this study, of which 9 subjects received cytarabine 1 g/m2 and 8 subjects received cytarabine administered at the maximum tolerable dose of 2 g/m2. All subjects discontinued the study treatment. The reasons for treatment discontinuation included disease progression (12 [70.6%] subjects), subjects proceeding to transplant (3 [17.6%]), investigator decision (1 [5.9%]), and “other” (1 [5.9%]). Reported adverse events were consistent with the known safety profile of Deitabine injection in adults (see section 4.8). Based on these negative results, Deitabine injection should not be used in children with AML aged < 18 years, because efficacy was not established (see section 4.2).

  • Pharmacokinetic properties

The population pharmacokinetic (PK) parameters of decitabine were pooled from 3 clinical studies in 45 patients with AML or myelodysplastic syndrome (MDS) utilizing the 5-Day regimen. In each study, decitabine PK was evaluated on the fifth day of the first treatment cycle.

Distribution

The pharmacokinetics of decitabine following intravenous administration as a 1-hour infusion were described by a linear two-compartment model, characterised by rapid elimination from the central compartment and by relatively slow distribution from the peripheral compartment. For a typical patient (weight 70 kg/body surface area 1.73 m2) the decitabine pharmacokinetic parameters are listed in the Table 3 below.

Table 3: Summary of population PK analysis for a typical patient receiving daily 1-hour infusions of Deitabine injection 20mg/m2 over 5 days every 4 weeks
Parameter a Predicted Value 95% CI
Cmax (ng/ml) 107 88.5 – 129
AUCcum (ng.h/ml) 580 480 – 695
t1/2 (min) 68.2 54.2 – 79.6
Vdss (L) 116 84.1 – 153
CL (L/h) 298 249 – 359
a The total dose per cycle was 100mg/m2

Decitabine exhibits linear PK and following the intravenous infusion, steady-state concentrations are reached within 0.5 hour. Based on model simulation, PK parameters were independent of time (i.e., did not change from cycle to cycle) and no accumulation was observed with this dosing regimen. Plasma protein binding of decitabine is negligible (< 1%). Decitabine Vdss in cancer patients is large indicating distribution into peripheral tissues. There was no evidence of dependencies on age, creatinine clearance, total bilirubin, or disease.

Biotransformation

Intracellularly, decitabine is activated through sequential phosphorylation via phosphokinase activities to the corresponding triphosphate, which is then incorporated by the DNA polymerase. In vitro metabolism data and the human mass balance study results indicated that the cytochrome P450 system is not involved in the metabolism of decitabine. The primary route of metabolism is likely through deamination by cytidine deaminase in the liver, kidney, intestinal epithelium and blood. Results from the human mass-balance study showed that unchanged decitabine in plasma accounted for approximately 2.4% of total radioactivity in plasma. The major circulating metabolites are not believed to be pharmacologically active. The presence of these metabolites in urine together with the high total body clearance and low urinary excretion of unchanged decitabine in the urine (~4% of the dose) indicate that decitabine is appreciably metabolized in vivoIn vitro studies show that decitabine does not inhibit nor induce CYP 450 enzymes up to more than 20-fold of the therapeutic maximum observed plasma concentration (Cmax). Thus; CYP-mediated metabolic drug interactions are not anticipated, and decitabine is unlikely to interact with agents metabolized through these pathways. In addition, in vitro data show that decitabine is a poor P-gp substrate.

Elimination

Mean plasma clearance following intravenous administration in cancer subjects was > 200 L/h with moderate inter-subject variability (coefficient of variation [CV] is approximately 50%). Excretion of unchanged drug appears to play only a minor role in the elimination of decitabine.

Results from a mass balance study with radioactive 14C-decitabine in cancer patients showed that 90% of the administered dose of decitabine (4% unchanged drug) is excreted in the urine.

Additional information on special populations

The effects of renal or hepatic impairment, gender, age or race on the pharmacokinetics of decitabine have not been formally studied. Information on special populations was derived from pharmacokinetic data from the 3 studies noted above, and from one Phase I study in MDS subjects, (N = 14; 15mg/m2 x 3-hours q8h x 3 days).

Elderly

Population pharmacokinetic analysis showed that decitabine pharmacokinetics are not dependent on age (range studied 40 to 87 years; median 70 years).

Paediatric population

Population PK analysis of decitabine showed that after accounting for body size, there is no difference between decitabine PK parameters in paediatric AML patients versus adults with AML or MDS.

Gender

Population pharmacokinetic analysis of decitabine did not show any clinically relevant difference between men and women.

Race

Most of the patients studied were Caucasian. However, the population pharmacokinetic analysis of decitabine indicated that race had no apparent effect on the exposure to decitabine.

Hepatic impairment

The PK of decitabine have not been formally studied in patients with hepatic impairment. Results from a human mass-balance study and in vitro experiments mentioned above indicated that the CYP enzymes are unlikely to be involved in the metabolism of decitabine. In addition, the limited data from the population PK analysis indicated no significant PK parameter dependencies on total bilirubin concentration despite a wide range of total bilirubin levels. Thus, decitabine exposure is not likely to be affected in patients with impaired hepatic function.

Renal impairment

The PK of decitabine have not been formally studied in patients with renal insufficiency. The population PK analysis on the limited decitabine data indicated no significant PK parameter dependencies on normalized creatinine clearance, an indicator of renal function. Thus, decitabine exposure is not likely to be affected in patients with impaired renal function.

  • Preclinical safety data

Formal carcinogenicity studies have not been performed with decitabine. Evidence from the literature indicates that decitabine has carcinogenic potential. The available data from in vitro and in vivo studies provide sufficient evidence that decitabine has genotoxic potential. Data from the literature also indicate that decitabine has adverse effects on all aspects of the reproductive cycle, including fertility, embryo-foetal development and post-natal development. Multi-cycle repeat-dose toxicity studies in rats and rabbits indicated that the primary toxicity was myelosuppression, including effects on bone marrow, which was reversible on cessation of treatment. Gastrointestinal toxicity was also observed and in males, testicular atrophy which did not reverse over the scheduled recovery periods. Decitabine administration to neonatal/juvenile rats showed a comparable general toxicity profile as in older rats. Neurobehavioural development and reproductive capacity were unaffected when neonatal/juvenile rats were treated at dose levels inducing myelosuppression. See section 4.2 for information on paediatric use.

  1. Pharmaceutical particulars
    • List of excipients

Potassium dihydrogen phosphate

Sodium hydroxide

Hydrochloric acid (for pH adjustment)

  • Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

  • Shelf life

Unopened vial

3 years.

Reconstituted and diluted solution

Within 15 minutes of reconstitution, the concentrate (in 10ml of sterile water for injections) must be further diluted with cold (2°C – 8°C) infusion fluids. This prepared diluted solution for intravenous infusion can be stored at 2°C – 8°C for up to a maximum of 3 hours, followed by up to 1 hour at room temperature (20°C – 25°C) before administration.

From a microbiological point of view, the product should be used within the time period recommended above. It is the responsibility of the user to follow the recommended storage times and conditions and ensure that reconstitution has taken place in aseptic conditions.

  • Special precautions for storage

Do not store above 25°C.

For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.

  • Nature and contents of container

20ml clear colourless Type I glass vial sealed with a butyl rubber stopper and an aluminium seal with plastic flip-off cap containing 50mg decitabine.

Pack size: 1 vial.

  • Special precautions for disposal and other handling

Recommendations for safe handling

Skin contact with the solution should be avoided and protective gloves must be worn. Standard procedures for dealing with cytotoxic medicinal products should be adopted.

Reconstitution procedure

The powder should be aseptically reconstituted with 10ml of water for injections. Upon reconstitution, eachml contains approximately 5mg of decitabine at pH 6.7 to 7.3. Within 15 minutes of reconstitution, the solution must be further diluted with cold infusion fluids (sodium chloride 9mg/ml [0.9%] solution for injection or 5% glucose solution for injection) to a final concentration of 0.15 to 1.0mg/ml. For the shelf-life and the precaution for storage after reconstitution, see section 6.3.

Deitabine injection should not be infused through the same intravenous access/line with other medicinal products.

Disposal

This medicinal product is for single use only. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Manufactured in India By:
TAJ PHARMACEUTICALS LIMITED
at SURVEY NO.188/1 TO 189/1,190/1 TO 4,
ATHIYAWAD, DABHEL, DAMAN- 396210 (INDIA)

Deitabine for Injection 50mg/Vial Taj Pharma

Package leaflet: Information for the user

Decitabine
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

  1. What Deitabine injection is and what it is used for
  2. What you need to know before you use Deitabine injection
  3. How to use Deitabine injection
  4. Possible side effects
  5. How to store Deitabine injection
  6. Contents of the pack and other information

1.      What Deitabine injection is and what it is used for

What Deitabine injection is

Deitabine injection is an anti-cancer medicine. It contains the active substance ‘decitabine’.

What Deitabine injection is used for

Deitabine injection is used to treat a type of cancer called ‘acute myeloid leukaemia’ or ‘AML’. This is a type of cancer that affects your blood cells. You will be given Deitabine injection when you are first diagnosed with AML. It is used in adults.

How Deitabine injection works

Deitabine injection works by stopping cancer cells from growing. It also kills cancer cells.

Talk to your doctor or nurse if you have any questions about how Deitabine injection works or why this medicine has been prescribed for you.

  1. What you need to know before you are given Deitabine injection

Do not use Deitabine injection:

  • if you are allergic to decitabine or any of the other ingredients of this medicine (listed in section 6).
  • if you are breast-feeding.

If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Deitabine injection.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using Deitabine injection if you have

  • low numbers of platelets, red blood cells or white blood cells,
  • an infection,
  • liver disease,
  • a serious kidney disorder,
  • a heart disorder.

If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Deitabine injection.

Tests or checks

You will have blood tests before you start treatment with Deitabine injection and at the start of each treatment cycle. These tests are to check that:

  • you have enough blood cells, and
  • your liver and kidneys are working properly.

Talk to your doctor about what your blood test results mean.

Children and adolescents

Deitabine injection is not for use in children or adolescents under the age of 18.

Other medicines and Deitabine injection

Tell your doctor, nurse or pharmacist if you are using, have recently used or might use any other medicines. This includes medicines obtained without a prescription and herbal medicines. This is because Deitabine injection can affect the way some other medicines work. Also, some other medicines can affect the way Deitabine injection works.

Pregnancy and breast-feeding

  • If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
  • You should not use Deitabine injection if you are pregnant as it may harm your baby. Tell your doctor immediately if you become pregnant during treatment with Deitabine injection.
  • Do not breast-feed if you are using Deitabine injection. This is because it is not known if the medicine passes into the mother’s milk.

Male and female fertility and contraception

  • Men should not father a child while using Deitabine injection.
  • Men should use effective contraception during treatment and for up to 3 months after treatment has stopped.
  • Talk to your doctor if you wish to conserve your sperm before starting treatment.
  • Women must use effective contraception during treatment. It is unknown when it is safe for women to become pregnant after treatment has stopped.
  • Talk to your doctor if you wish to freeze your eggs before starting treatment.

Driving and using machines

You may feel tired or weak after using Deitabine injection. If this happens, do not drive or use any tools or machines.

Deitabine injection contains potassium and sodium

  • This medicine contains 0.5 mmol potassium in each vial. After preparing the medicine, it contains less than 1 mmol (39mg) of potassium per dose, i.e. essentially ‘potassium- free’.
  • This medicine contains 0.29 mmol (6.67mg) sodium (main component of cooking/table salt) in each vial. After preparing the medicine, it contains between 13.8mg-138mg sodium per dose , equivalent to 0.7-7% of the recommended maximum daily dietary intake of sodium for an adult. Talk to your doctor if you are on a low salt diet.
  1. How to use Deitabine injection

Deitabine injection will be given to you by a doctor or nurse who is trained in giving this type of medicine.

How much to use

  • Your doctor will work out your dose of Deitabine injection. This depends on your height and weight (body surface area).
  • The dose is 20mg/m2 body surface area.
  • You will receive Deitabine injection every day for 5 days, then 3 weeks without the medicine. This is called a ‘treatment cycle’ and it is repeated every 4 weeks. You will usually receive at least 4 treatment cycles.
  • Your doctor may delay your dose and change the total number of cycles, depending on how you respond to the treatment.

How Deitabine injection is given

The solution is given into a vein (as an infusion). This will take one hour.

If you are given more Deitabine injection than you should

This medicine will be given by your doctor or nurse. In the unlikely event that you are given too much (an overdose) your doctor will check you for side effects and manage them accordingly.

If you forget your appointment to have Deitabine injection

If you miss an appointment, make another one as soon as possible. This is because for this medicine to be as effective as possible, it is important to follow the dosing schedule.

If you have any further questions on the use of this medicine, ask your doctor or nurse.

  1. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine.

Tell your doctor or nurse immediately if you notice any of the following serious side effects

  • Fever: this may be a sign of an infection caused by low levels of white blood cells (very common).
  • Chest pain or shortness of breath (with or without fever or cough): these may be signs of an infection of the lung called “pneumonia” (very common) or inflamed lungs (interstitial lung disease [frequency not known]) or cardiomyopathy (heart muscle disease [uncommon]) which can be accompanied with swelling of ankles, hands, legs and feet.
  • Bleeding: including blood in the stools. This may be a sign of bleeding in the stomach or gut (common).
  • Difficultly with moving, speaking or understanding or seeing; sudden severe headache, seizure, numbness or weakness in any part of the body. These may be signs of bleeding inside your head (common).
  • Difficulty breathing, swelling of the lips, itching or rash: This may be due to an allergic (hypersensitivity) reaction (common).

Tell your doctor or nurse immediately if you notice any of the serious side effects above.

Other side effects of Deitabine injection include

Very common (may affect more than 1 in 10 people)

  • Urine infection
  • Other infection in any part of the body, caused by bacteria, virus or fungi
  • bleeding or bruising more easily – these may be signs of a drop in the number of blood platelets
  • (thrombocytopaenia)
  • feeling tired or looking pale – these may be signs of a drop in the number of red blood cells
  • (anaemia)
  • high level of sugar in the blood
  • headache
  • nose bleeds
  • diarrhoea
  • vomiting
  • nausea
  • fever
  • abnormal liver function

Common (may affect up to 1 in 10 people)

  • an infection of the blood caused by bacteria – this may be a sign of a low level of white blood cells
  • sore or runny nose, sore sinuses
  • mouth or tongue ulcers
  • high level of ‘bilirubin’ in the blood

Uncommon (may affect up to 1 in 100 people)

  • a drop in the number of red blood cells, white blood cells and platelets (pancytopaenia)
  • heart muscle disease
  • red, raised painful patches on the skin, fever, an increase in white blood cells – these may be signs of ‘Acute Febrile Neutrophilic Dermatosis’ or ‘Sweet’s Syndrome’

Not known (frequency cannot be estimated from the available data)

  • inflamed gut (enterocolitis, colitis and caecitis), with symptoms of abdominal pain, bloating, or diarrhoea. Enterocolitis may lead to septic complications and may be associated with fatal outcome.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

  1. How to store Deitabine injection
  • Your doctor, nurse or pharmacist is responsible for storing Deitabine injection.
  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date, which is stated on the carton and on the vial label after EXP. The expiry date refers to the last day of that month.
  • Do not store above 250
  • After reconstitution, the concentrate must be further diluted within 15 minutes using cold infusion fluids. This prepared diluted solution can be stored refrigerated at 2°C – 8°C for up to a maximum of 3 hours, followed by up to 1 hour at room temperature (20°C – 25°C) before administration.
  • Your doctor, nurse or pharmacist is responsible for disposing of any unused Deitabine injection correctly.
  1. Contents of the pack and other information

What Deitabine injection contains

  • The active substance is decitabine. Each vial of powder contains 50mg decitabine. After reconstitution with 10ml of water for injections, each ml of concentrate contains 5mg of decitabine.
  • The other ingredients are potassium dihydrogen phosphate, sodium hydroxide, and hydrochloric acid (for pH-adjustment). See section 2.

What Deitabine injection looks like and contents of the pack

Deitabine injection is a white to almost white powder for concentrate for solution for infusion. It is supplied in a 20ml glass vial containing 50mg decitabine. Each pack contains 1 vial.

Manufactured in India By:
TAJ PHARMACEUTICALS LIMITED
at SURVEY NO.188/1 TO 189/1,190/1 TO 4,
ATHIYAWAD, DABHEL, DAMAN- 396210 (INDIA)

 

Related Products

Taj Generics (Taj Pharma) provides a wide range of products to the Indian market, including an extensive range of generics and specialty products; Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. Our Generics portfolio offers over 1500 products in the major therapeutic areas of gastro-intestinal, cardiovascular, pain management, oncology, anti-infectives, paediatrics and dermatology.